Measles, Mumps, and Rubella - Centers for Disease Control and ...
Measles, Mumps, and Rubella - Centers for Disease Control and ...
Measles, Mumps, and Rubella - Centers for Disease Control and ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
50 MMWR May 22, 199856. Krugman S. Further-attenuated measles vaccine: characteristics <strong>and</strong> use. Rev Infect Dis 1983;5:477–81.57. Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D. Persistence of measlesantibody after revaccination. J Infect Dis 1992;166:205–8.58. Mathias RG, Meekison WG, Arc<strong>and</strong> TA, Schechter MA. The role of secondary vaccine failuresin measles outbreaks. Am J Public Health 1989;79:475–8.59. Edmonson MB, Davis JP, Hopfensperger DJ, Berg JL, Payton LA. <strong>Measles</strong> vaccination duringthe respiratory virus season <strong>and</strong> risk of vaccine failure. Pediatrics 1996;98:905–10.60. Balfour HH, Groth KE, Edelman CK. RA27/3 rubella vaccine. Am J Dis Child 1990;134:350–3.61. Grillner L, Hedstrom E-E, Bergstrom H, et al. Vaccination against rubella of newly deliveredwomen. Sc<strong>and</strong> J Infect Dis 1973;5:237–41.62. Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hinman AR. Clinical <strong>and</strong> laboratorystudies of live attenuated RA 27/3 <strong>and</strong> HPV 77-DE rubella virus vaccines. Proc Soc Exp BiolMed 1980;165:44–9.63. Balfour HH Jr, Groth KE, Edelman CK, Amren DP, Best JM, Banatvala JE. <strong>Rubella</strong> viraemia<strong>and</strong> antibody responses after rubella vaccination <strong>and</strong> reimmunization. Lancet 1981;1078–80.64. O’Shea S, Best JM, Banatvala JE. Viremia, virus excretion, <strong>and</strong> antibody responses after challengein volunteers with low levels of antibody to rubella virus. J Infect Dis 1983;148:639–47.65. Greaves WL, Orenstein WA, Hinman AR, Nersesian WS. Clinical efficacy of rubella vaccine.Pediatr Infect Dis 1983;2:284–6.66. Baba K, Yabuuchi H, Okuni H, et al. <strong>Rubella</strong> epidemic in an institution: protective value oflive rubella vaccine <strong>and</strong> serological behavior of vaccinated, revaccinated, <strong>and</strong> naturally immunegroups. Biken J 1978;21:25–31.67. Maes EF, Gillan A, Stehr-Green PA, Stewart SS, Markowitz LE, Patriarca PA. <strong>Rubella</strong> antibodypersistence 20 years after immunization [Abstract]. In: Program <strong>and</strong> abstracts of the 31st InterscienceCongress on Antimicrobial Agents <strong>and</strong> Chemotherapy. Washington, DC: AmericanSociety <strong>for</strong> Microbiology, 1991.68. Orenstein WA, Herrman KL, Holmgreen P, et al. Prevalence of rubella antibodies in Massachusettsschoolchildren. Am J Epidemiol 1986;124: 290–8.69. Horstmann DM, Schluederberg A, Emmons JE, Evans BK, R<strong>and</strong>olph MF, Andiman WA. Persistenceof vaccine-induced immune responses to rubella: comparison with natural infection.Rev Infect Dis 1985;7:580–5.70. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA 27/3 rubella virus vaccine.A comparison with strains presently licensed in the U.S. JAMA 1973;225:585–90.71. Best JM, Banatvala JE, Morgan-Capner P, et al. Fetal infection after maternal reinfection withrubella: criteria <strong>for</strong> defining reinfection. Br Med J 1989;299:773–5.72. Weibel RE, Sokes J Jr, Buynak EB, Whitman JE Jr, Hilleman MR. Live, attenuated mumps-virusvaccine: 3. Clinical <strong>and</strong> serologic aspects in a field situation. N Engl J Med 1967;276:245–51.73. Hilleman MR, Weibel RE, Buynak EB, Stokes J Jr, Whitman JE Jr. Live attenuated mumps-virusvaccine: 4. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252–8.74. Sugg WC, Finger JA, Levine RH, Pagano JS. Field evaluation of live virus mumps vaccine.J Pediatr 1968;72:461–6.75. Kim-Farley R, Bart S, Stetler H, et al. Clinical mumps vaccine efficacy. Am J Epidemiol 1985;121:593–7.76. Weibel RE, Buyak EB, McLean AA, Roehm RR, Hilleman MR. Follow-up surveillance <strong>for</strong> antibodyin human subjects following live attenuated measles, mumps, <strong>and</strong> rubella virus vaccines. ProcSoc Exp Biol Med 1979;162:328–32.77. Weibel RE, Buyak EB, McLean, Roehm RR, Hilleman MR. Persistence of antibody in humansubjects <strong>for</strong> 7 to 10 years following administration of combined live attenuated measles,mumps, <strong>and</strong> rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:260–3.78. CDC. <strong>Mumps</strong> surveillance—United States, 1988–93. MMWR 1995;44(SS-3):1–14.79. Cochi SL, Wharton M, Plotkin SA. <strong>Mumps</strong> vaccine. In Plotkin SA, Mortimer EA, eds. Vaccines.2nd ed. Philadelphia, WB Saunders, 1988:277–301.80. CDC. General recommendations on immunization: recommendations of the Advisory Committeeon Immunization Practices (ACIP). MMWR 1994;43(No. RR-1):1–38.
Change language